{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:46:09Z","timestamp":1782395169453,"version":"3.54.5"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s11255-019-02183-5","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T18:46:51Z","timestamp":1559414811000},"page":"1089-1099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics"],"prefix":"10.1007","volume":"51","author":[{"given":"Aleksander","family":"\u015alusarczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0569-4203","authenticated-orcid":false,"given":"Piotr","family":"Zapa\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Zapa\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Piecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Radziszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"issue":"2","key":"2183_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstrom","year":"2009","unstructured":"Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette\u2013Guerin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247\u2013256","journal-title":"Eur Urol"},{"issue":"5","key":"2183_CR2","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Da Silva CF, Powell PH et al (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette\u2013Guerin, and bacillus Calmette\u2013Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57(5):766\u2013773","journal-title":"Eur Urol"},{"issue":"2","key":"2183_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.eururo.2015.07.010","volume":"69","author":"TC Zuiverloon","year":"2016","unstructured":"Zuiverloon TC, Zwarthoff EC (2016) Predicting response to intravesical bacillus Calmette\u2013Guerin immunotherapy: are we moving forward? Eur Urol 69(2):201\u2013202","journal-title":"Eur Urol"},{"issue":"6","key":"2183_CR4","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1097\/01.ju.0000066840.42991.4a","volume":"169","author":"M Peyromaure","year":"2003","unstructured":"Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M (2003) Intravesical bacillus Calmette\u2013Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J Urol 169(6):2110\u20132112","journal-title":"J Urol"},{"issue":"3","key":"2183_CR5","doi-asserted-by":"publisher","first-page":"108 e1","DOI":"10.1016\/j.urolonc.2014.02.020","volume":"33","author":"HW Herr","year":"2015","unstructured":"Herr HW, Milan TN, Dalbagni G (2015) BCG-refractory vs BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. Urol Oncol 33(3):108 e1\u2013108 e4","journal-title":"Urol Oncol"},{"issue":"8","key":"2183_CR6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/j.1464-410X.2009.08543.x","volume":"104","author":"L Barlow","year":"2009","unstructured":"Barlow L, McKiernan J, Sawczuk I, Benson M (2009) A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette\u2013Guerin therapy. BJU Int 104(8):1098\u20131102","journal-title":"BJU Int"},{"issue":"3","key":"2183_CR7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/bju.13088","volume":"117","author":"PA Cockerill","year":"2016","unstructured":"Cockerill PA, Knoedler JJ, Frank I, Tarrell R, Karnes RJ (2016) Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. BJU Int 117(3):456\u2013462","journal-title":"BJU Int"},{"issue":"8","key":"2183_CR8","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/cncr.24914","volume":"116","author":"G Di Lorenzo","year":"2010","unstructured":"Di Lorenzo G, Perdona S, Damiano R, Faiella A, Cantiello F, Pignata S et al (2010) Gemcitabine versus bacille Calmette\u2013Guerin after initial bacille Calmette\u2013Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 116(8):1893\u20131900","journal-title":"Cancer"},{"issue":"4","key":"2183_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","volume":"182","author":"O Nativ","year":"2009","unstructured":"Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A et al (2009) Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette\u2013Guerin. J Urol 182(4):1313\u20131317","journal-title":"J Urol"},{"issue":"6","key":"2183_CR10","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","volume":"62","author":"DR Yates","year":"2012","unstructured":"Yates DR, Brausi MA, Catto JW, Dalbagni G, Roupret M, Shariat SF et al (2012) Treatment options available for bacillus Calmette\u2013Guerin failure in non-muscle-invasive bladder cancer. Eur Urol 62(6):1088\u20131096","journal-title":"Eur Urol"},{"issue":"2","key":"2183_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3233\/BLC-150020","volume":"1","author":"S Patel","year":"2015","unstructured":"Patel S, Dinh T, Noah-Vanhoucke J, Rengarajan B, Mayo K, Clark PE et al (2015) Novel simulation model of non-muscle invasive bladder cancer: a platform for a virtual randomized trial of conservative therapy vs. cystectomy in BCG refractory patients. Bladder Cancer 1(2):143\u2013150","journal-title":"Bladder Cancer"},{"issue":"1","key":"2183_CR12","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","volume":"18","author":"M Racioppi","year":"2018","unstructured":"Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF (2018) ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3\u00a0years follow-up outcomes. BMC Cancer 18(1):1224","journal-title":"BMC Cancer"},{"issue":"3","key":"2183_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013475 (discussion 75\u201377)","journal-title":"Eur Urol"},{"issue":"5","key":"2183_CR14","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette\u2013Guerin: the CUETO scoring model. J Urol 182(5):2195\u20132203","journal-title":"J Urol"},{"issue":"6","key":"2183_CR15","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/bjc.2013.372","volume":"109","author":"E Xylinas","year":"2013","unstructured":"Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS et al (2013) Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 109(6):1460\u20131466","journal-title":"Br J Cancer"},{"key":"2183_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.11.005","author":"V Soukup","year":"2018","unstructured":"Soukup V, Capoun O, Cohen D, Hernandez V, Burger M, Comperat E et al (2018) Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European association of urology non-muscle-invasive bladder cancer guidelines panel. Eur Urol Focus. \n                    https:\/\/doi.org\/10.1016\/j.euf.2018.11.005","journal-title":"Eur Urol Focus"},{"key":"2183_CR17","first-page":"195","volume":"9","author":"S Holz","year":"2017","unstructured":"Holz S, Albisinni S, Gilsoul J, Pirson M, Duthie V, Quackels T et al (2017) Risk factor assessment in high-risk, bacillus Calmette\u2013Guerin-treated, non-muscle-invasive bladder cancer. Res Rep Urol 9:195\u2013202","journal-title":"Res Rep Urol"},{"issue":"1","key":"2183_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G et al (2016) EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette\u2013Guerin. Eur Urol 69(1):60\u201369","journal-title":"Eur Urol"},{"issue":"3","key":"2183_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1464-410X.2009.09137.x","volume":"106","author":"SA Boorjian","year":"2010","unstructured":"Boorjian SA, Zhu F, Herr HW (2010) The effect of gender on response to bacillus Calmette\u2013Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int 106(3):357\u2013361","journal-title":"BJU Int"},{"issue":"1","key":"2183_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","volume":"62","author":"J Palou","year":"2012","unstructured":"Palou J, Sylvester RJ, Faba OR, Parada R, Pena JA, Algaba F et al (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette\u2013Guerin. Eur Urol 62(1):118\u2013125","journal-title":"Eur Urol"},{"issue":"5","key":"2183_CR21","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00345-012-0996-9","volume":"31","author":"LA Kluth","year":"2013","unstructured":"Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Roupret M et al (2013) Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol 31(5):1029\u20131036","journal-title":"World J Urol"},{"issue":"5","key":"2183_CR22","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","volume":"53","author":"J Fernandez-Gomez","year":"2008","unstructured":"Fernandez-Gomez J, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Hernandez R et al (2008) Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette\u2013Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 53(5):992\u20131001","journal-title":"Eur Urol"},{"issue":"5","key":"2183_CR23","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00345-013-1037-z","volume":"31","author":"G Gakis","year":"2013","unstructured":"Gakis G, Stenzl A (2013) Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity. World J Urol 31(5):1059\u20131064","journal-title":"World J Urol"},{"issue":"1","key":"2183_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.urolonc.2009.01.033","volume":"29","author":"C Tuygun","year":"2011","unstructured":"Tuygun C, Kankaya D, Imamoglu A, Sertcelik A, Zengin K, Oktay M et al (2011) Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 29(1):43\u201351","journal-title":"Urol Oncol"},{"key":"2183_CR25","doi-asserted-by":"publisher","first-page":"E2186","DOI":"10.3390\/ijms18102186","volume":"18","author":"M Miyake","year":"2017","unstructured":"Miyake M, Tatsumi Y, Gotoh D, Ohnishi S, Owari T, Iida K et al (2017) Regulatory T cells and tumor-associated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical bacille Calmette\u2013Guerin: a long-term follow-up study of a Japanese cohort. Int J Mol Sci 18:E2186. \n                    https:\/\/doi.org\/10.3390\/ijms18102186","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2183_CR26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","volume":"33","author":"W Martin-Doyle","year":"2015","unstructured":"Martin-Doyle W, Leow JJ, Orsola A, Chang SL, Bellmunt J (2015) Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 33(6):643\u2013650","journal-title":"J Clin Oncol"},{"issue":"4","key":"2183_CR27","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.eururo.2014.05.033","volume":"66","author":"JR Oddens","year":"2014","unstructured":"Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G et al (2014) The effect of age on the efficacy of maintenance bacillus Calmette\u2013Guerin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol 66(4):694\u2013701","journal-title":"Eur Urol"},{"issue":"1","key":"2183_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","volume":"19","author":"J Nikolich-Zugich","year":"2018","unstructured":"Nikolich-Zugich J (2018) The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol 19(1):10\u201319","journal-title":"Nat Immunol"},{"issue":"1","key":"2183_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.urology.2007.03.024","volume":"70","author":"HW Herr","year":"2007","unstructured":"Herr HW (2007) Age and outcome of superficial bladder cancer treated with bacille Calmette\u2013Guerin therapy. Urology 70(1):65\u201368","journal-title":"Urology"},{"issue":"3","key":"2183_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00345-018-2397-1","volume":"37","author":"M Ferro","year":"2019","unstructured":"Ferro M, Vartolomei MD, Russo GI, Cantiello F, Farhan ARA, Terracciano D et al (2019) An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World J Urol. 37(3):507\u2013514","journal-title":"World J Urol"},{"issue":"3","key":"2183_CR31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2174\/1871530318666180131094733","volume":"18","author":"MD Borges","year":"2018","unstructured":"Borges MD, Franca EL, Fujimori M, Silva SMC, de Marchi PGF, Deluque AL et al (2018) Relationship between proinflammatory cytokines\/chemokines and adipokines in serum of young adults with obesity. Endocr Metab Immune Disord Drug Targets 18(3):260\u2013267","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"2","key":"2183_CR32","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.juro.2013.01.089","volume":"190","author":"LA Kluth","year":"2013","unstructured":"Kluth LA, Xylinas E, Crivelli JJ, Passoni N, Comploj E, Pycha A et al (2013) Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. J Urol 190(2):480\u2013486","journal-title":"J Urol"},{"key":"2183_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cca.2018.01.039","volume":"480","author":"Y Lin","year":"2018","unstructured":"Lin Y, Wang Y, Wu Q, Jin H, Ma G, Liu H et al (2018) Association between obesity and bladder cancer recurrence: a meta-analysis. Clin Chim Acta 480:41\u201346","journal-title":"Clin Chim Acta"},{"issue":"1","key":"2183_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12894-018-0404-x","volume":"18","author":"I Getzler","year":"2018","unstructured":"Getzler I, Bahouth Z, Nativ O, Rubinstein J, Halachmi S (2018) Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer. BMC Urol 18(1):90","journal-title":"BMC Urol"},{"issue":"4","key":"2183_CR35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298\u2013306","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2183_CR36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.clgc.2018.07.003","volume":"16","author":"MD Vartolomei","year":"2018","unstructured":"Vartolomei MD, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R et al (2018) Validation of neutrophil-to-lymphocyte ratio in a multi-institutional cohort of patients with T1G3 non-muscle-invasive bladder cancer. Clin Genitourin Cancer 16(6):445\u2013452","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"2183_CR37","doi-asserted-by":"publisher","first-page":"483 e17","DOI":"10.1016\/j.urolonc.2016.05.013","volume":"34","author":"A Mbeutcha","year":"2016","unstructured":"Mbeutcha A, Shariat SF, Rieken M, Rink M, Xylinas E, Seitz C et al (2016) Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. Urol Oncol 34(11):483 e17\u2013483 e24","journal-title":"Urol Oncol"},{"issue":"9","key":"2183_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.urolonc.2018.05.014","volume":"36","author":"MD Vartolomei","year":"2018","unstructured":"Vartolomei MD, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B et al (2018) Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis. Urol Oncol 36(9):389\u2013399","journal-title":"Urol Oncol"},{"issue":"1","key":"2183_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/bju.13354","volume":"118","author":"P Gontero","year":"2016","unstructured":"Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V et al (2016) The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade\/Grade 3 bladder cancer treated with bacille Calmette\u2013Guerin. BJU Int 118(1):44\u201352","journal-title":"BJU Int"},{"issue":"1","key":"2183_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12957-018-1310-0","volume":"16","author":"P Zapala","year":"2018","unstructured":"Zapala P, Dybowski B, Poletajew S, Bialek L, Niewczas A, Radziszewski P (2018) Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer. World J Surg Oncol 16(1):6","journal-title":"World J Surg Oncol"},{"key":"2183_CR41","first-page":"269","volume":"6","author":"N Vasdev","year":"2012","unstructured":"Vasdev N, Dominguez-Escrig J, Paez E, Johnson MI, Durkan GC, Thorpe AC (2012) The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer. Ecancermedicalscience 6:269","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"2183_CR42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3109\/01913123.2013.770111","volume":"37","author":"F Ajili","year":"2013","unstructured":"Ajili F, Kourda N, Karay S, Darouiche A, Chebil M, Boubaker S (2013) Impact of smoking intensity on outcomes of patients with non muscle invasive bladder cancer treated by BCG immunotherapy. Ultrastruct Pathol 37(4):273\u2013277","journal-title":"Ultrastruct Pathol"},{"issue":"2","key":"2183_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1464-410X.2007.06873.x","volume":"100","author":"CH Chen","year":"2007","unstructured":"Chen CH, Shun CT, Huang KH, Huang CY, Tsai YC, Yu HJ et al (2007) Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int 100(2):281\u2013286 (discussion 6)","journal-title":"BJU Int"},{"issue":"4","key":"2183_CR44","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1464-410X.2010.09874.x","volume":"108","author":"JP Sfakianos","year":"2011","unstructured":"Sfakianos JP, Shariat SF, Favaretto RL, Rioja J, Herr HW (2011) Impact of smoking on outcomes after intravesical bacillus Calmette\u2013Guerin therapy for urothelial carcinoma not invading muscle of the bladder. BJU Int 108(4):526\u2013530","journal-title":"BJU Int"},{"issue":"6","key":"2183_CR45","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.eururo.2012.08.057","volume":"62","author":"M Rink","year":"2012","unstructured":"Rink M, Xylinas E, Babjuk M, Pycha A, Karakiewicz PI, Novara G et al (2012) Smoking reduces the efficacy of intravesical bacillus Calmette\u2013Guerin immunotherapy in non-muscle-invasive bladder cancer. Eur Urol 62(6):1204\u20131206","journal-title":"Eur Urol"},{"issue":"5","key":"2183_CR46","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nri803","volume":"2","author":"M Sopori","year":"2002","unstructured":"Sopori M (2002) Effects of cigarette smoke on the immune system. Nat Rev Immunol 2(5):372\u2013377","journal-title":"Nat Rev Immunol"},{"issue":"25","key":"2183_CR47","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1056\/NEJMc062714","volume":"355","author":"P Hoffmann","year":"2006","unstructured":"Hoffmann P, Roumeguere T, Schulman C, van Velthoven R (2006) Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 355(25):2705\u20132707","journal-title":"N Engl J Med"},{"issue":"12","key":"2183_CR48","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1056\/NEJMc070117","volume":"356","author":"AM Kamat","year":"2007","unstructured":"Kamat AM, Wu X (2007) Statins and the effect of BCG on bladder cancer. N Engl J Med. 356(12):1276 (author reply-7)","journal-title":"N Engl J Med."},{"issue":"6","key":"2183_CR49","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.urology.2012.09.065","volume":"81","author":"MJ Lipsky","year":"2013","unstructured":"Lipsky MJ, Badalato GM, Motamedinia P, Hruby GW, McKiernan JM (2013) The effect of fibrin clot inhibitors on the immunomodulatory efficacy of bacillus Calmette\u2013Guerin therapy for non-muscle-invasive bladder cancer. Urology 81(6):1273\u20131278","journal-title":"Urology"},{"issue":"9","key":"2183_CR50","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1097\/MD.0000000000000589","volume":"94","author":"F Dal Moro","year":"2015","unstructured":"Dal Moro F, Bovo A, Crestani A, Vettor R, Gardiman MP, Zattoni F (2015) Effect of hypertension on outcomes of high-risk patients after BCG-treated bladder cancer: a single-institution long follow-up cohort study. Medicine (Baltimore) 94(9):e589","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2183_CR51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","volume":"69","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras Gonzalez GM, Anderson R et al (2016) Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette\u2013Guerin. Eur Urol 69(2):197\u2013200","journal-title":"Eur Urol"},{"issue":"6","key":"2183_CR52","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1200\/JCO.1996.14.6.1778","volume":"14","author":"R Kaempfer","year":"1996","unstructured":"Kaempfer R, Gerez L, Farbstein H, Madar L, Hirschman O, Nussinovich R et al (1996) Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 14(6):1778\u20131786","journal-title":"J Clin Oncol"},{"issue":"1","key":"2183_CR53","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","volume":"61","author":"TC Zuiverloon","year":"2012","unstructured":"Zuiverloon TC, Nieuweboer AJ, Vekony H, Kirkels WJ, Bangma CH, Zwarthoff EC (2012) Markers predicting response to bacillus Calmette\u2013Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61(1):128\u2013145","journal-title":"Eur Urol"},{"issue":"2","key":"2183_CR54","doi-asserted-by":"publisher","first-page":"e1265719","DOI":"10.1080\/2162402X.2016.1265719","volume":"6","author":"K Qu","year":"2017","unstructured":"Qu K, Gu J, Ye Y, Williams SB, Dinney CP, Wu X et al (2017) High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette\u2013Guerin therapy: a long-term survival analysis. Oncoimmunology 6(2):e1265719","journal-title":"Oncoimmunology"},{"key":"2183_CR55","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-18-0893","author":"A Salmasi","year":"2018","unstructured":"Salmasi A, Elashoff DA, Guo R, Upfill-Brown A, Rosser CJ, Rose JM et al (2018) Urinary cytokine profile to predict response to intravesical BCG with or without HS-410 therapy in patients with non-muscle invasive bladder cancer. Cancer Epidemiol Biomark Prev. \n                    https:\/\/doi.org\/10.1158\/1055-9965.EPI-18-0893","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"6","key":"2183_CR56","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","volume":"164","author":"GN Thalmann","year":"2000","unstructured":"Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG, Studer UE (2000) Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette\u2013Guerin. J Urol 164(6):2129\u20132133","journal-title":"J Urol"},{"issue":"1","key":"2183_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000477673","volume":"99","author":"S Poletajew","year":"2017","unstructured":"Poletajew S, Zapala P, Radziszewski P (2017) Safety and efficacy of intravesical bacillus Calmette\u2013Guerin immunotherapy in patients with non-muscle-invasive bladder cancer presenting with asymptomatic bacteriuria: a systematic review. Urol Int 99(1):1\u20135","journal-title":"Urol Int"},{"issue":"5","key":"2183_CR58","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/bju.13186","volume":"117","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Willis DL, Dickstein RJ, Anderson R, Nogueras-Gonzalez G, Katz RL et al (2016) Novel fluorescence in situ hybridization-based definition of bacille Calmette\u2013Guerin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU Int 117(5):754\u2013760","journal-title":"BJU Int"},{"issue":"36","key":"2183_CR59","doi-asserted-by":"publisher","first-page":"e12227","DOI":"10.1097\/MD.0000000000012227","volume":"97","author":"Y Bao","year":"2018","unstructured":"Bao Y, Tu X, Chang T, Qiu S, Yang L, Geng J et al (2018) The role of fluorescence in situ hybridization to predict patient response to intravesical bacillus Calmette\u2013Guerin therapy for bladder cancer: a diagnostic meta-analysis and systematic review. Medicine (Baltimore). 97(36):e12227","journal-title":"Medicine (Baltimore)."},{"issue":"10","key":"2183_CR60","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12032-017-1033-z","volume":"34","author":"E Liem","year":"2017","unstructured":"Liem E, Baard J, Cauberg ECC, Bus MTJ, de Bruin DM, Laguna Pes MP et al (2017) Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with bacillus Calmette\u2013Guerin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer. Med Oncol 34(10):172","journal-title":"Med Oncol"},{"issue":"6","key":"2183_CR61","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.eururo.2009.01.040","volume":"55","author":"C Ayari","year":"2009","unstructured":"Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A et al (2009) Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette\u2013Guerin immunotherapy. Eur Urol 55(6):1386\u20131395","journal-title":"Eur Urol"},{"issue":"26","key":"2183_CR62","doi-asserted-by":"publisher","first-page":"39916","DOI":"10.18632\/oncotarget.9537","volume":"7","author":"R Pichler","year":"2016","unstructured":"Pichler R, Fritz J, Zavadil C, Schafer G, Culig Z, Brunner A (2016) Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus Calmette\u2013Guerin therapy in bladder cancer. Oncotarget 7(26):39916\u201339930","journal-title":"Oncotarget"},{"issue":"4","key":"2183_CR63","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00262-016-1945-z","volume":"66","author":"R Pichler","year":"2017","unstructured":"Pichler R, Gruenbacher G, Culig Z, Brunner A, Fuchs D, Fritz J et al (2017) Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunol Immunother 66(4):427\u2013440","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2183_CR64","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/j.urolonc.2013.06.008","volume":"32","author":"R Nunez-Nateras","year":"2014","unstructured":"Nunez-Nateras R, Castle EP, Protheroe CA, Stanton ML, Ocal TI, Ferrigni EN et al (2014) Predicting response to bacillus Calmette\u2013Guerin (BCG) in patients with carcinoma in situ of the bladder. Urol Oncol 32(1):e23\u2013e30","journal-title":"Urol Oncol"},{"issue":"5","key":"2183_CR65","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.juro.2007.07.041","volume":"178","author":"T Cai","year":"2007","unstructured":"Cai T, Mazzoli S, Meacci F, Tinacci G, Nesi G, Zini E et al (2007) Interleukin-6\/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma. J Urol 178(5):1906\u20131911 (discussion 11\u201312)","journal-title":"J Urol"},{"issue":"3","key":"2183_CR66","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3892\/etm.2012.634","volume":"4","author":"T Cai","year":"2012","unstructured":"Cai T, Nesi G, Mazzoli S, Meacci F, Tinacci G, Luciani LG et al (2012) Prediction of response to bacillus Calmette\u2013Guerin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio. Exp Ther Med 4(3):459\u2013464","journal-title":"Exp Ther Med"},{"key":"2183_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12957-016-0890-9","volume":"14","author":"J Du","year":"2016","unstructured":"Du J, Wang SH, Yang Q, Chen QQ, Yao X (2016) p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis. World J Surg Oncol 14:137","journal-title":"World J Surg Oncol"},{"issue":"4","key":"2183_CR68","doi-asserted-by":"publisher","first-page":"e019635","DOI":"10.1136\/bmjopen-2017-019635","volume":"8","author":"Y He","year":"2018","unstructured":"He Y, Wang N, Zhou X, Wang J, Ding Z, Chen X et al (2018) Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review. BMJ Open 8(4):e019635","journal-title":"BMJ Open"},{"issue":"10","key":"2183_CR69","first-page":"4201","volume":"29","author":"L Cormio","year":"2009","unstructured":"Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F et al (2009) Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res 29(10):4201\u20134204","journal-title":"Anticancer Res"},{"issue":"1","key":"2183_CR70","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.eururo.2012.05.033","volume":"65","author":"S Bertz","year":"2014","unstructured":"Bertz S, Otto W, Denzinger S, Wieland WF, Burger M, Stohr R et al (2014) Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur Urol 65(1):218\u2013226","journal-title":"Eur Urol"},{"issue":"5","key":"2183_CR71","doi-asserted-by":"publisher","first-page":"242 e9","DOI":"10.1016\/j.urolonc.2018.02.002","volume":"36","author":"IM El-Babouly","year":"2018","unstructured":"El-Babouly IM, Desoky EAE, El Sayed D, Ali MM, Harb OA, Ragab A et al (2018) The role of neural precursor cell-expressed developmentally down-regulated protein 9 in predicting bacillus Calmette\u2013Guerin response in nonmuscle invasive bladder cancer. Urol Oncol 36(5):242 e9\u2013242 e14","journal-title":"Urol Oncol"},{"issue":"3","key":"2183_CR72","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00262-017-2093-9","volume":"67","author":"J Breyer","year":"2018","unstructured":"Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R et al (2018) High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunol Immunother 67(3):403\u2013412","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2183_CR73","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi BP et al (2016) Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30(1):27\u201342","journal-title":"Cancer Cell"},{"issue":"8","key":"2183_CR74","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA 111(8):3110\u20133115","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2183_CR75","doi-asserted-by":"publisher","first-page":"701 e7","DOI":"10.1016\/j.ccell.2017.08.005","volume":"32","author":"CD Hurst","year":"2017","unstructured":"Hurst CD, Alder O, Platt FM, Droop A, Stead LF, Burns JE et al (2017) Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. Cancer Cell 32(5):701 e7\u2013715 e7","journal-title":"Cancer Cell"},{"issue":"11","key":"2183_CR76","doi-asserted-by":"publisher","first-page":"e0165856","DOI":"10.1371\/journal.pone.0165856","volume":"11","author":"D Kim","year":"2016","unstructured":"Kim D, Choi Y, Ireland J, Foreman O, Tam RN, Patel R et al (2016) Development and application of a microfluidics-based panel in the basal\/luminal transcriptional characterization of archival bladder cancers. PLoS One 11(11):e0165856","journal-title":"PLoS One"},{"issue":"5","key":"2183_CR77","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00428-018-2354-9","volume":"472","author":"I Barth","year":"2018","unstructured":"Barth I, Schneider U, Grimm T, Karl A, Horst D, Gaisa NT et al (2018) Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. Virchows Arch 472(5):749\u2013758","journal-title":"Virchows Arch"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02183-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02183-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02183-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T23:11:55Z","timestamp":1590880315000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02183-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":77,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["2183"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02183-5","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]},"assertion":[{"value":"21 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Piotr Zapa\u0142a, \u0141ukasz Zapa\u0142a, Tomasz Piecha and Piotr Radziszewski declare that they participate in clinical trial assessing efficacy and safety of durvalumab and receive fees as clinical investigators from AstraZeneca on that account.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}